 |
Prospector
Profile
3-27-002
|
| |
| Panacos Pharmaceuticals, Inc. |
NAICS |
541710 |
| 134 Coolidge Avenue,
Watertown, MA 02472 |
Description |
Biotechnology |
| (617) 926-1551 |
Employees |
41 |
| http://www.panacos.com/ |
Revenue |
(mil) |
0.1800 |
| |
Income |
(mil) |
-37.4600 |
| |
Assets |
(mil) |
55.7100 |
| |
Liability |
(mil) |
26.8400 |
| |
(for the year ended 2007-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Panacos Pharmaceuticals, Inc., reported a net loss of $37.46 million for fiscal year ended December 31, 2007, compared to a net loss of $38.11 million in 2006 and $59.08 million in 2005. As a result of its recurring losses, the Company has an accumulated deficit of $160.02 million as of December 31, 2007. The Company also used cash for operating activities of $31.04 million in 2007, compared to $29.63 million in 2006 and $21.65 million in 2005.
|
| |
|
Intellectual Property:
The Company seeks to protect proprietary technology that is important to its business, including compounds, formulations and their methods of use. In addition to seeking patent protection in the U.S., the Company also files patent applications in European countries and additional foreign countries, including Australia, Canada and Japan, on a selective basis. It relies upon trade secrets and contracts and confidentiality agreements to protect proprietary information. Currently, the Company's patent estate in antiviral therapeutics includes 11 issued U.S. patents and 15 pending U.S. applications. It also maintains a separate docket of 13 patent families claiming aspects of the INACTINE program. Each of the U.S. applications and patents has one or more corresponding foreign applications or patents. [SEC Filing 10-K 03-07-08]
|
| |
|
Description:
Panacos Pharmaceuticals, Inc., engages in the discovery and development of small molecule oral drugs to treat human immunodeficiency virus (HIV) and other major human viral diseases.
|
| |
|
Officers:
Jeremy Hayward-Surry (Chair); Alan W. Dunton, M.D. (Pres., CEO & Dir.); Jane Pritchett Henderson (EVP, CFO, Chief Business Officer, Treas. & Sec.); Robert B. Pelletier (VP-Finance); Irwin Lerner (Dir.); Joseph M. Limber (Dir.); R. John Fletcher (Dir.); Robert G. Savage (Dir.); Laurent Fischer, M.D. (Dir.)
|
| |
|
Auditor:
KPMG LLP
|
| |
|
Securities:
Common Stock-Symbol PANC; NasdaqGM; 53,544,834 common shares outstanding as of February 29, 2008.
|
| |
| |
| |
| return to main page |
|
|
